A Phase 3 interventional study of Rotigotine and Placebo in Restless Legs Syndrome and End-Stage Renal Disease, sponsored by UCB BIOSCIENCES GmbH. Completed at 15 sites in 6 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-11-03.
Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 15th largest by enrollment, is one of 3 that started in 2012, is one of 10 in phase 3, and was the 13th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2012.
This study's enrollment of 30 is below the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under UCB BIOSCIENCES GmbH, one of the names counted as UCB S.A.. Under that name alone:
UCB BIOSCIENCES GmbH is the lead sponsor of 21 studies on the registry; none are open to participants now.
17 studies in Restless Legs Syndrome by UCB S.A.: none open now, none under way, none of them phase 3. Of 17 finished, 11 (65%) have results posted.
Among the 17 studies in Restless Legs Syndrome by UCB S.A., this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2012, is one of 9 in phase 3, and was the 14th registered.
UCB S.A.’s Restless Legs Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 17 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a sleep laboratory study to evaluate the efficacy and safety of Rotigotine in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysis.
The objectives are to demonstrate superiority of Rotigotine against Placebo as well as to investigate the effect of Rotigotine on quality of life and sleep.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rotigotine Transdermal Patch 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.
Drug: Rotigotine
Transdermal patch matched according to patch size and appearance.
Drug: Placebo
Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h. Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal.
Also known as: Neupro
Transdermal patch; Patches matching to active treatment patches in size and appearance. Up to 3 weeks of Titration, 2 weeks of Maintenance, Up to 4 days of Taper Period.
Ratio From Baseline to the End of the 2-week Maintenance Period in Periodic Limb Movement Index (PLMI)
The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). The reduction of the PLMI is reflected in terms of the ratio from Baseline to the end of the Maintenance Period and was calculated as \[PLMI at end of Maintenance Period (MP)\] / \[PLMI at Baseline\]. A PLMI Ratio \<1 indicates an improvement from Baseline to the end of the 2-week MP.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Periodic Limb Movements Index (PLMI) to the End of the Maintenance Period
The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). A negative value in change from Baseline indicates an improvement from Baseline to the end of the Maintenance Period.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the International Restless Legs Syndrome Study Group Rating Scale (IRLS) Sum Score to the End of the Maintenance Period
The IRLS is a subject based scale that consists of 10 items to evaluate the severity of major RLS symptoms and the impact of the disease on subjects' functioning in daytime activities. Each of the 10 items is measured on a scale that ranges from 0 (not present) to 4 (severe). A sum score between 0 (no RLS symptoms present at all) and 40 (maximum severity in all symptoms) across all 10 items will be calculated. A negative value in Change from Baseline indicates an improvement from Baseline in IRLS.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in Clinical Global Impressions (CGI) Item 1 Score
The CGI Item 1 score measures the severity of illness on a scale that ranges from 0 (Not assessed) to 7 (Among the most extremely ill).
Time frame: Visit 2 (Baseline); Visit 6 (End of Maintence Period)
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 1 to the End of the Maintenance Period
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 1 measures satisfaction with sleep during the last seven nights on an 11-point scale that ranges between 0 (completely satisfied) to 10 (completely dissatisfied). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 2 to the End of the Maintenance Period
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 2 measures the severity of RLS symptoms during the last 7 nights in the situation of falling asleep. This is measured on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 3 to the End of the Maintenance Period
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 3 measures the severity of RLS symptoms during the last seven nights on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 4 to the End of the Maintenance Period
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 4 measures the severity of RLS symptoms during the last seven days at rest on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 5 to the End of the Maintenance Period
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 5 measures the severity of RLS symptoms during the last seven days engaged in activities on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 6 to the End of the Maintenance Period
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 6 measures the severity of daytime tiredness/ sleepiness on an 11-point scale that ranges between 0 (not at all) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Periodic Limb Movement During Sleep Arousal Index (PLMSAI) to the End of the Maintenance Period
The Periodic Limb Movement during Sleep Arousal Index (PLMSAI) reflects the influence of the PLM on subject's sleep. Arousal is defined as sudden change in the Electroencephalogram (EEG) activity and the index illustrates to what degree the PLMs contribute to arousal from sleep. A negative value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in Sleep Efficiency to the End of the Maintenance Period
Sleep stages and time spent in each sleep stage are determined from Electroencephalogram (EEG) readings. Sleep stage data will be used to calculate sleep efficiency. Sleep efficiency will be presented as percentages. Sleep efficiency is the percentage of time in bed spent asleep. A postive value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Restless Legs-Quality of Life (RLS-QoL) Total Score to the End of the Maintenance Period
The RLS-QoL is a disease-specific questionnaire to evaluate quality of life. It consists of 12 items. A total score will be calculated from all of the 12 items. The overall sum score can be from 0 (highest QoL) to 60 (lowest QoL). A negative value in Change from Baseline indicates an improvement from Baseline.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Mental Component Summary (MCS) to the End of the Maintenance Period
The SF-36 is a 36 item generic human research quality of life instrument that uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and a further unscaled single item (question 2) for perceived stability or change in health (Health Transition) during the last year. The norm based scores (based on the US general population) were used for analysis. For the MCS, the lowest and highest possible scores are -9 and 82 (rounded). The SF-36 domains (subscores) are scored so that a higher score indicates a better health state.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Physical Component Summary (PCS) to the End of the Maintenance Period
The SF-36 is a 36 item generic human research quality of life instrument that uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and a further unscaled single item (question 2) for perceived stability or change in health (Health Transition) during the last year. The norm-based scores (based on the US general population) were used for analysis. For the PCS, the lowest and highest possible scores are 1 and 81 (rounded). The SF-36 domains (subscores) are scored so that a higher score indicates a better health state.
Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
The recruitment for the SP0934 study began in April 2012. It concluded in October 2013. This was a multicenter study with subjects enrolled by 9 sites across Europe and 6 sites across the United States.
| Milestone | Placebo | Rotigotine |
|---|---|---|
| Started | 10 | 20 |
| Completed | 10 | 15 |
| Not completed | 0 | 5 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Other | 0 | 1 |
The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). The reduction of the PLMI is reflected in terms of the ratio from Baseline to the end of the Maintenance Period and was calculated as \[PLMI at end of Maintenance Period (MP)\] / \[PLMI at Baseline\]. A PLMI Ratio \<1 indicates an improvement from Baseline to the end of the 2-week MP.
| ratio | Placebo | Rotigotine |
|---|---|---|
| Ratio From Baseline to the End of the 2-week Maintenance Period in Periodic Limb Movement Index (PLMI) | 1.16 (0.68 to 1.99) | 0.51 (0.33 to 0.80) |
The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). A negative value in change from Baseline indicates an improvement from Baseline to the end of the Maintenance Period.
| movement/ hour | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Periodic Limb Movements Index (PLMI) to the End of the Maintenance Period | 10.3 ± 21 | -23.7 ± 38.7 |
The IRLS is a subject based scale that consists of 10 items to evaluate the severity of major RLS symptoms and the impact of the disease on subjects' functioning in daytime activities. Each of the 10 items is measured on a scale that ranges from 0 (not present) to 4 (severe). A sum score between 0 (no RLS symptoms present at all) and 40 (maximum severity in all symptoms) across all 10 items will be calculated. A negative value in Change from Baseline indicates an improvement from Baseline in IRLS.
| units on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the International Restless Legs Syndrome Study Group Rating Scale (IRLS) Sum Score to the End of the Maintenance Period | -8.6 ± 7.2 | -15.9 ± 9.1 |
The CGI Item 1 score measures the severity of illness on a scale that ranges from 0 (Not assessed) to 7 (Among the most extremely ill).
| participants | Placebo (Visit 2) | Rotigotine (Visit 2) | Placebo (Visit 6) | Rotigotine (Visit 6) |
|---|---|---|---|---|
| Not assessed | 0 | 0 | 0 | 0 |
| Normal, not ill at all | 0 | 0 | 1 | 5 |
| Borderline ill | 0 | 0 | 1 | 4 |
| Mildly ill | 0 | 0 | 3 | 3 |
| Moderately ill | 3 | 3 | 5 | 1 |
| Markedly ill | 5 | 9 | 0 | 2 |
| Severely ill | 2 | 2 | 0 | 0 |
| Among the most extremely ill subjects | 0 | 1 | 0 | 0 |
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 1 measures satisfaction with sleep during the last seven nights on an 11-point scale that ranges between 0 (completely satisfied) to 10 (completely dissatisfied). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 1 to the End of the Maintenance Period | -1.1 ± 3.5 | -2.8 ± 3.2 |
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 2 measures the severity of RLS symptoms during the last 7 nights in the situation of falling asleep. This is measured on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 2 to the End of the Maintenance Period | -2.8 ± 2.9 | -4.4 ± 2.9 |
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 3 measures the severity of RLS symptoms during the last seven nights on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 3 to the End of the Maintenance Period | -3.2 ± 2.6 | -4.7 ± 3.1 |
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 4 measures the severity of RLS symptoms during the last seven days at rest on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 4 to the End of the Maintenance Period | -1.6 ± 3.2 | -2.6 ± 2.2 |
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 5 measures the severity of RLS symptoms during the last seven days engaged in activities on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 5 to the End of the Maintenance Period | -1.6 ± 2.1 | -1.6 ± 2.7 |
The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 6 measures the severity of daytime tiredness/ sleepiness on an 11-point scale that ranges between 0 (not at all) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.
| units on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 6 to the End of the Maintenance Period | -1.6 ± 2.0 | -3.4 ± 2.3 |
The Periodic Limb Movement during Sleep Arousal Index (PLMSAI) reflects the influence of the PLM on subject's sleep. Arousal is defined as sudden change in the Electroencephalogram (EEG) activity and the index illustrates to what degree the PLMs contribute to arousal from sleep. A negative value in Change from Baseline indicates an improvement from Baseline.
| movement per hour | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Periodic Limb Movement During Sleep Arousal Index (PLMSAI) to the End of the Maintenance Period | 4.634 ± 7.162 | -1.609 ± 14.412 |
Sleep stages and time spent in each sleep stage are determined from Electroencephalogram (EEG) readings. Sleep stage data will be used to calculate sleep efficiency. Sleep efficiency will be presented as percentages. Sleep efficiency is the percentage of time in bed spent asleep. A postive value in Change from Baseline indicates an improvement from Baseline.
| sleep time/ total time in bed | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in Sleep Efficiency to the End of the Maintenance Period | -2.850 ± 10.347 | 7.668 ± 12.317 |
The RLS-QoL is a disease-specific questionnaire to evaluate quality of life. It consists of 12 items. A total score will be calculated from all of the 12 items. The overall sum score can be from 0 (highest QoL) to 60 (lowest QoL). A negative value in Change from Baseline indicates an improvement from Baseline.
| scores on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Restless Legs-Quality of Life (RLS-QoL) Total Score to the End of the Maintenance Period | -10.2 ± 10.8 | -10.7 ± 10.9 |
The SF-36 is a 36 item generic human research quality of life instrument that uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and a further unscaled single item (question 2) for perceived stability or change in health (Health Transition) during the last year. The norm based scores (based on the US general population) were used for analysis. For the MCS, the lowest and highest possible scores are -9 and 82 (rounded). The SF-36 domains (subscores) are scored so that a higher score indicates a better health state.
| units on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Mental Component Summary (MCS) to the End of the Maintenance Period | 6.4 ± 6.6 | 2.2 ± 10.1 |
The SF-36 is a 36 item generic human research quality of life instrument that uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and a further unscaled single item (question 2) for perceived stability or change in health (Health Transition) during the last year. The norm-based scores (based on the US general population) were used for analysis. For the PCS, the lowest and highest possible scores are 1 and 81 (rounded). The SF-36 domains (subscores) are scored so that a higher score indicates a better health state.
| units on a scale | Placebo | Rotigotine |
|---|---|---|
| Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Physical Component Summary (PCS) to the End of the Maintenance Period | -0.3 ± 8.7 | 3.8 ± 6.3 |
Collected over Adverse Events were recorded during the course of the SP0934 study, which began in April 2012 and concluded in October 2013.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/10 (10%) | 4/10 (40%) |
| Rotigotine | — | 3/20 (15%) | 12/20 (60%) |
| Event | Placebo | Rotigotine |
|---|---|---|
| Gastrointestinal infectionInfections and infestations | 1/10 | 0/20 |
| Abdominal painGastrointestinal disorders | 0/10 | 1/20 |
| Chest painGeneral disorders | 0/10 | 1/20 |
| Foot fractureInjury, poisoning and procedural complications | 0/10 | 1/20 |
| AnxietyPsychiatric disorders | 0/10 | 1/20 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/10 | 1/20 |
| Event | Placebo | Rotigotine |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/10 | 1/20 |
| NauseaGastrointestinal disorders | 0/10 | 4/20 |
| VomitingGastrointestinal disorders | 0/10 | 3/20 |
| FatigueGeneral disorders | 1/10 | 0/20 |
| Oedema peripheralGeneral disorders | 1/10 | 0/20 |
| HeadacheNervous system disorders | 0/10 | 2/20 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/10 | 2/20 |
| HypertensionVascular disorders | 0/10 | 2/20 |
| Eye haemorrhageEye disorders | 0/10 | 1/20 |
| ConstipationGastrointestinal disorders | 0/10 | 1/20 |
The baseline analysis population consisted of the Safety Set (SS), which is all subjects who were randomized and had at least 1 patch applied during the Treatment Period.
| Age, Continuous(years) | Placebo | Rotigotine | Total |
|---|---|---|---|
| Mean | 50.7 ± 16.3 | 57.2 ± 12.6 | 55.0 ± 14.0 |
| Age, Categorical(Participants) | Placebo | Rotigotine | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 15 | 23 |
| >=65 years | 2 | 5 | 7 |
| Sex: Female, Male(Participants) | Placebo | Rotigotine | Total |
|---|---|---|---|
| Female | 3 | 7 | 10 |
| Male | 7 | 13 | 20 |
| Race (NIH/OMB)(Participants) | Placebo | Rotigotine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 6 | 8 |
| White | 4 | 13 | 17 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Rotigotine | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 5 | 16 | 21 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Region of Enrollment(participants) | Placebo | Rotigotine | Total |
|---|---|---|---|
| United States | 6 | 12 | 18 |
| Europe | 4 | 8 | 12 |
| Weight(Kilograms) | Placebo | Rotigotine | Total |
|---|---|---|---|
| Mean | 85.38 ± 20.99 | 89.42 ± 15.34 | 88.07 ± 17.17 |
| Height(Centimeters) | Placebo | Rotigotine | Total |
|---|---|---|---|
| Mean | 171.77 ± 8.59 | 171.50 ± 11.99 | 171.59 ± 10.82 |
1 further baseline measures are reported on the registry.
The record gives a start of Apr 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine